Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SR18662 是 ML264 类似物,可抑制 Krüppel 样因子 5 (KLF5),IC50 为 4.4 nM,降低多种结直肠癌细胞系的活力并诱导细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 397 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,660 | 现货 | ||
25 mg | ¥ 3,320 | 现货 | ||
50 mg | ¥ 5,320 | 现货 | ||
100 mg | ¥ 7,290 | 现货 | ||
200 mg | ¥ 9,830 | 现货 | ||
500 mg | ¥ 14,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | SR18662, an optimized compund based on ML264 that inhibits Krüppel-like factor 5 (KLF5) with IC50 of 4.4 nM, reduces the viability of multiple colorectal cancer cell lines and induces apoptosis. |
靶点活性 | KLF5:4.4 nM |
体外活性 | SR18662 significantly reduces growth and proliferation of CRC cells and shows improved efficacy in reducing viability of multiple CRC cell lines. Flow cytometry analysis following SR18662 treatment shows an increase in cells captured in either S or G2/M phases of the cell cycle and a significant increase in the number of apoptotic cells. SR18662 also reduces the expression of cyclins and components of WNT and MAPK signaling pathways.[1] |
体内活性 | The effect of SR18662 treatment shows a significant dose-dependent inhibition of xenograft growth in mice and exceeds ML264 at equivalent doses. SR18662 is potential for colorectal cancer therapy.[1] |
细胞实验 | Cell lines: HT29, HCT116, DLD-1 and SW620 colorectal cancer cell lines. Concentrations: 0.001 μM-20 μM. Incubation Time: 24 h. Method: KLF5 promoter activity assay: DLD-1/pGL4.18hKLF5p cells are seeded in 96 well plate and treated with SR18662 dissolved in DMSO in the range of 0.001 to 20 μM or equivalent volume of DMSO as control for 24 h, the human KLF5 promoter activity is determined with the ONE-Glo luciferase assay system by a SpectramMax M3 plate reader. |
动物实验 | Animal Models: 7-week-old male NuJ/Foxn1nu mice with DLD-1 human colorectal cells injected. Dosages: 5 mg/kg, 10 mg/kg, 25 mg/kg. Administration: I.P. |
分子量 | 420.31 |
分子式 | C16H19Cl2N3O4S |
CAS No. | T22429 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 120mg/mL (285.50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3792 mL | 11.896 mL | 23.792 mL | 59.4799 mL |
5 mM | 0.4758 mL | 2.3792 mL | 4.7584 mL | 11.896 mL | |
10 mM | 0.2379 mL | 1.1896 mL | 2.3792 mL | 5.948 mL | |
20 mM | 0.119 mL | 0.5948 mL | 1.1896 mL | 2.974 mL | |
50 mM | 0.0476 mL | 0.2379 mL | 0.4758 mL | 1.1896 mL | |
100 mM | 0.0238 mL | 0.119 mL | 0.2379 mL | 0.5948 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SR18662 T22429 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis SR 18662 SR-18662 Inhibitor inhibitor inhibit